These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

179 related items for PubMed ID: 7530170

  • 1. Treatment of low-grade non-Hodgkin's lymphoma with continuous infusion of low-dose recombinant interleukin-2 in combination with the B-cell-specific monoclonal antibody CLB-CD19.
    Vlasveld LT, Hekman A, Vyth-Dreese FA, Melief CJ, Sein JJ, Voordouw AC, Dellemijn TA, Rankin EM.
    Cancer Immunol Immunother; 1995 Jan; 40(1):37-47. PubMed ID: 7530170
    [Abstract] [Full Text] [Related]

  • 2. Potentiation by interleukin 2 of Burkitt's lymphoma therapy with anti-pan B (anti-CD19) monoclonal antibodies in a mouse xenotransplantation model.
    Vuist WM, v Buitenen F, de Rie MA, Hekman A, Rümke P, Melief CJ.
    Cancer Res; 1989 Jul 15; 49(14):3783-8. PubMed ID: 2472198
    [Abstract] [Full Text] [Related]

  • 3. Clinical and immunologic effects of prolonged infusion of low-dose recombinant interleukin-2 after autologous and T-cell-depleted allogeneic bone marrow transplantation.
    Soiffer RJ, Murray C, Cochran K, Cameron C, Wang E, Schow PW, Daley JF, Ritz J.
    Blood; 1992 Jan 15; 79(2):517-26. PubMed ID: 1730094
    [Abstract] [Full Text] [Related]

  • 4. The efficacy of CD3 x CD19 bispecific monoclonal antibody (BsAb) in a clonogenic assay: the effect of repeated addition of BsAb and interleukin-2.
    Haagen IA, Geerars AJ, de Lau WB, Bast BJ, de Gast BC.
    Blood; 1995 Jun 01; 85(11):3208-12. PubMed ID: 7538821
    [Abstract] [Full Text] [Related]

  • 5. Enhanced antitumor effects of CD20 over CD19 monoclonal antibodies in a nude mouse xenograft model.
    Hooijberg E, van den Berk PC, Sein JJ, Wijdenes J, Hart AA, de Boer RW, Melief CJ, Hekman A.
    Cancer Res; 1995 Feb 15; 55(4):840-6. PubMed ID: 7531616
    [Abstract] [Full Text] [Related]

  • 6. Eradication of large human B cell tumors in nude mice with unconjugated CD20 monoclonal antibodies and interleukin 2.
    Hooijberg E, Sein JJ, van den Berk PC, Hart AA, van der Valk MA, Kast WM, Melief CJ, Hekman A.
    Cancer Res; 1995 Jun 15; 55(12):2627-34. PubMed ID: 7540106
    [Abstract] [Full Text] [Related]

  • 7. Lysis of malignant B cells from patients with B-chronic lymphocytic leukemia by autologous T cells activated with CD3 x CD19 bispecific antibodies in combination with bivalent CD28 antibodies.
    Bohlen H, Hopff T, Manzke O, Engert A, Kube D, Wickramanayake PD, Diehl V, Tesch H.
    Blood; 1993 Sep 15; 82(6):1803-12. PubMed ID: 7691238
    [Abstract] [Full Text] [Related]

  • 8. Rituximab: a review of its use in non-Hodgkin's lymphoma and chronic lymphocytic leukaemia.
    Plosker GL, Figgitt DP.
    Drugs; 2003 Sep 15; 63(8):803-43. PubMed ID: 12662126
    [Abstract] [Full Text] [Related]

  • 9. In vitro and in vivo antitumor activity of a chimeric anti-CD19 antibody.
    Pietersz GA, Wenjun L, Sutton VR, Burgess J, McKenzie IF, Zola H, Trapani JA.
    Cancer Immunol Immunother; 1995 Jul 15; 41(1):53-60. PubMed ID: 7543822
    [Abstract] [Full Text] [Related]

  • 10. Independent expression of p55 and p75 interleukin-2 receptors (IL-2R) during intravenous or subcutaneous administration of recombinant interleukin-2 (rIL-2) by T-lymphocytes and natural killer cells.
    Zambello R, Trentin L, Cerutti A, Enthammer C, Milani A, Franceschi T, Messina C, Cetto GL, Agostini C, Semenzato G.
    Cancer; 1994 Nov 01; 74(9):2562-9. PubMed ID: 7522954
    [Abstract] [Full Text] [Related]

  • 11. Preclinical investigation of the antitumour effects of anti-CD19-idarubicin immunoconjugates.
    Rowland AJ, Pietersz GA, McKenzie IF.
    Cancer Immunol Immunother; 1993 Aug 01; 37(3):195-202. PubMed ID: 7687521
    [Abstract] [Full Text] [Related]

  • 12. Lymphocyte activation and serine-esterase induction following recombinant interleukin-2 infusion for lymphomas and acute leukaemias.
    Lim SH, Worman C, Jewell A, Tsakona C, Giles FJ, Goldstone A.
    Cancer Immunol Immunother; 1991 Aug 01; 33(2):133-7. PubMed ID: 2036661
    [Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 9.